Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.27) per share.
Related Posts
Baird Maintains Outperform on Workiva, Raises Price Target to $100
Baird analyst Rob Oliver maintains Workiva (NYSE:WK) with a Outperform and raises the price target from $96 to $100.
Garrett Motion Clocks 14% Sales Decline In Q4; Bottom-Line Exceeds Expectation
Garrett Motion Inc (NASDAQ:GTX) reported a fourth-quarter sales decline of 14% year-over-year to $862 million, -13% on a constant currency basis,…
Morgan Stanley Maintains Overweight on Accolade, Raises Price Target to $68
Morgan Stanley analyst Ricky Goldwasser maintains Accolade (NASDAQ:ACCD) with a Overweight and raises the price target from $60 to $68.